These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 32179081)

  • 21. Successful secukinumab treatment of active bullous pemphigoid and chronic severe psoriasis: a case report.
    Yun JS; Scardamaglia L; Tan CG; McCormack CJ
    Australas J Dermatol; 2022 May; 63(2):e155-e158. PubMed ID: 35138643
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dupilumab combined with low-dose systemic steroid therapy improves efficacy and safety for bullous pemphigoid.
    Yang J; Gao H; Zhang Z; Tang C; Chen Z; Wang L; Yang F; Chen S; He S; Liu S; Tang L; Xu Y; Hu Y; Ma L; Zhao Y; Luo X
    Dermatol Ther; 2022 Aug; 35(8):e15648. PubMed ID: 35715972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Severe pemphigoid nodularis successfully treated with dupilumab.
    Jendoubi F; Bost C; Tournier E; Paul C; Konstantinou MP
    Dermatol Ther; 2022 Sep; 35(9):e15727. PubMed ID: 35861645
    [No Abstract]   [Full Text] [Related]  

  • 24. Successful treatment of eczema-like bullous pemphigoid and typical bullous pemphigoid with dupilumab: two case reports.
    Xu Y; Song W; Cai Y; Huang R; Wei J; Liu H; Peng X; Zeng K; Li C
    Int J Dermatol; 2023 Mar; 62(3):e144-e146. PubMed ID: 36214412
    [No Abstract]   [Full Text] [Related]  

  • 25. Reply to: 'Severe bullous pemphigoid following Covid-19 vaccination resistant to rituximab and successfully treated with dupilumab' by Baffa et al.
    Sun L; Brazão C; Mancha D; Soares-de-Almeida L; Filipe P
    J Eur Acad Dermatol Venereol; 2023 May; 37(5):e578-e580. PubMed ID: 36681888
    [No Abstract]   [Full Text] [Related]  

  • 26. Efficacy and safety of methotrexate, omalizumab and dupilumab for bullous pemphigoid in patients resistant or contraindicated to oral steroids. A monocentric real-life study.
    Velin M; Dugourd PM; Sanchez A; Bahadoran P; Montaudié H; Passeron T
    J Eur Acad Dermatol Venereol; 2022 Jul; 36(7):e539-e542. PubMed ID: 35143077
    [No Abstract]   [Full Text] [Related]  

  • 27. A successful case of vesicular pemphigoid concurrent with pulmonary tuberculosis with dupilumab.
    Shan Y; Zuo YG
    Dermatol Ther; 2022 Apr; 35(4):e15330. PubMed ID: 35080079
    [No Abstract]   [Full Text] [Related]  

  • 28. Dupilumab for the Treatment of Recalcitrant Bullous Pemphigoid.
    Kaye A; Gordon SC; Deverapalli SC; Her MJ; Rosmarin D
    JAMA Dermatol; 2018 Oct; 154(10):1225-1226. PubMed ID: 30140849
    [No Abstract]   [Full Text] [Related]  

  • 29. Successful management of severe infant bullous pemphigoid with omalizumab.
    Dufour C; Souillet AL; Chaneliere C; Jouen F; Bodemer C; Jullien D; Cambazard F; Joly P; Reix P
    Br J Dermatol; 2012 May; 166(5):1140-2. PubMed ID: 22098309
    [No Abstract]   [Full Text] [Related]  

  • 30. Successful treatment of bullous pemphigoid with omalizumab.
    London VA; Kim GH; Fairley JA; Woodley DT
    Arch Dermatol; 2012 Nov; 148(11):1241-3. PubMed ID: 23165827
    [No Abstract]   [Full Text] [Related]  

  • 31. PD-L1 positive macrophages were increased in a case of pembrolizumab-induced bullous pemphigoid.
    Nakai K; Sato Y; Kubo S; Tsuruta D
    J Dermatol; 2021 Mar; 48(3):e146-e148. PubMed ID: 33439513
    [No Abstract]   [Full Text] [Related]  

  • 32. Omalizumab as an alternative therapeutic tool in the treatment of bullous pemphigoid: A case report.
    Vico-Alonso C; Calleja-Algarra A; Aragón-Miguel R; Sánchez-Velázquez A; Velasco-Tamariz V; Ortiz-Romero PL; Monsálvez-Honrubia V
    Dermatol Ther; 2019 Mar; 32(2):e12829. PubMed ID: 30659716
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efalizumab-induced bullous pemphigoid.
    Duong TA; Buffard V; André C; Ortonne N; Revuz J; Bagot M; Roujeau JC
    J Am Acad Dermatol; 2010 Jan; 62(1):161-162. PubMed ID: 20082902
    [No Abstract]   [Full Text] [Related]  

  • 34. Pembrolizumab-Induced Bullous Pemphigoid Treated With Rituximab.
    Sharma P; Barnes M; Nabeel S; LiPera W
    JCO Oncol Pract; 2020 Nov; 16(11):764-766. PubMed ID: 32716760
    [No Abstract]   [Full Text] [Related]  

  • 35. The Anti-C1s Antibody TNT003 Prevents Complement Activation in the Skin Induced by Bullous Pemphigoid Autoantibodies.
    Kasprick A; Holtsche MM; Rose EL; Hussain S; Schmidt E; Petersen F; Panicker S; Ludwig RJ
    J Invest Dermatol; 2018 Feb; 138(2):458-461. PubMed ID: 28899686
    [No Abstract]   [Full Text] [Related]  

  • 36. [EFFECTIVE TREATMENT FOR BULLOUS PEMPHIGOID WITH OMALIZUMAB].
    Neumark M; Tal Y; Zlotogorski A; Molho-Pessach V
    Harefuah; 2020 Jan; 159(1):29-30. PubMed ID: 31930804
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Self-resolving bullous pemphigoid induced by cemiplimab.
    Molle MF; Capurro N; Herzum A; Micalizzi C; Cozzani E; Parodi A
    Dermatol Ther; 2022 Jun; 35(6):e15466. PubMed ID: 35320611
    [No Abstract]   [Full Text] [Related]  

  • 38. Severe treatment-resistant acute and recurrent vesicular chronic hand eczema successfully treated with dupilumab.
    Halling AS; Zachariae C; Thyssen JP
    Contact Dermatitis; 2020 Jul; 83(1):37-38. PubMed ID: 32087035
    [No Abstract]   [Full Text] [Related]  

  • 39. Incidental amelioration of bullous pemphigoid during ixekizumab treatment for psoriasis.
    Lu L; Yu Y; Zhang J; Fan X; Qi Y; Lin B
    J Dermatol; 2022 Jan; 49(1):e13-e15. PubMed ID: 34633684
    [No Abstract]   [Full Text] [Related]  

  • 40. Adjuvant treatment with secukinumab induced long term remission in a patient with severe bullous pemphigoid.
    Holtsche MM; Hammers CM; Chakievska L; Ludwig RJ; Thaci D; Zillikens D; Schmidt E
    J Dtsch Dermatol Ges; 2020 Dec; 18(12):1478-1480. PubMed ID: 32975029
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.